3 April 2019 - A proposal to require drug companies to pass discounts directly to Medicare patients at the point of sale would fundamentally change the role of medication rebates in Part D — and with it, drug pricing in general. 

How might it affect the program and its beneficiaries?

Read New England Journal of Medicine article (subscription required)